138028-00-9 (H-Ala-Pro-Arg-Thr-Pro-Gly-Gly-Arg-Arg-OH,MBP MAPK Substrate)

H-Ala-Pro-Arg-Thr-Pro-Gly-Gly-Arg-Arg-OH;

H-Ala-Pro-Arg-Thr-Pro-Gly-Gly-Arg-Arg-OH;CID 145707624;(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid;2,2,2-trifluoroacetic acid;Myelin Basic Protein (95-98) S5 Peptide MAP Kinase Substrate Trifluoroacetate;MBP MAPK Substrate;MS-31815;138028-00-9;AKOS040756706;Ala-Pro-Arg-Thr-Pro-Gly-Gly-Arg-Arg, synthetic, lyophilized powder;G12562;

YHKVFUUXPSSWNF-NRNNTDPLSA-N

1S/C39H70N18O11.C2HF3O2/c1-20(40)34(65)56-16-7-12-26(56)33(64)53-23(9-4-14-48-38(43)44)31(62)55-29(21(2)58)35(66)57-17-6-11-25(57)32(63)51-18-27(59)50-19-28(60)52-22(8-3-13-47-37(41)42)30(61)54-24(36(67)68)10-5-15-49-39(45)46;3-2(4,5)1(6)7/h20-26,29,58H,3-19,40H2,1-2H3,(H,50,59)(H,51,63)(H,52,60)(H,53,64)(H,54,61)(H,55,62)(H,67,68)(H4,41,42,47)(H4,43,44,48)(H4,45,46,49);(H,6,7)/t20-,21+,22-,23-,24-,25-,26-,29-;/m0./s1

FC(C(=O)O)(F)F.O=C([C@H]([C@@H](C)O)NC([C@H](CCC/N=C(\N)/N)NC([C@@H]1CCCN1C([C@H](C)N)=O)=O)=O)N1CCC[C@H]1C(NCC(NCC(N[C@H](C(N[C@H](C(=O)O)CCC/N=C(\N)/N)=O)CCC/N=C(\N)/N)=O)=O)=O